Figure S1. αPD-L1 inhibits TNBC malignant progression promoted by THP-1 (TAM/M2) cells. (A) CD68 (macrophage marker) expression was assessed using western blot analysis. (B) Protein expression levels of PD-L1, CD86, CD206, p-STAT3 and STAT3 in THP-1 cells treated with IL-13 (30 ng/ml) and/or αPD-L1 (15 μg/ml) were determined using western blot analysis. (C and D) MDA-MB-231 and Hs578T cell migratory capacity, when treated with THP-1 CM was assessed using wound healing and Transwell assays (magnification, x200). (E) Protein expression levels of EMT markers, E-cadherin, ZO-1, vimentin, Slug and Twist, in MDA-MB-231 and Hs578T cells treated with THP-1 CM, were assessed via western blotting. (F) Protein expression levels of the stemness markers, CD44, Oct4, Nanog and Bmi1 in MDA-MB-231 and Hs578T cells treated with THP-1 CM, were assessed using western blot analysis. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. αPD-L1, programmed cell death-ligand 1 inhibitor; TNBC, triple-negative breast cancer; TAM/M2, tumor-associated macrophages/M2-type; PD-L1, programmed cell death-ligand 1, p, phosphorylated; CM, conditional media; EMT, epithelial-mesenchymal transition; ZO-1, zonula occludens-1.



Figure S2. αPD-L1 inhibits the sphere-forming ability of TNBC cells promoted by TAM/M2. ***P<0.001. αPD-L1, programmed cell death-ligand 1 inhibitor; TNBC, triple-negative breast cancer; TAM/M2, tumor-associated macrophages/M2-type.